Literature DB >> 30391138

Trends in Renal-Cell Carcinoma Incidence and Mortality in the United States in the Last 2 Decades: A SEER-Based Study.

Anas M Saad1, Mohamed M Gad2, Muneer J Al-Husseini1, Inas A Ruhban3, Mohamad Bassam Sonbol4, Thai H Ho5.   

Abstract

BACKGROUND: Renal-cell carcinoma (RCC) is one of the common malignancies in the United States. RCC incidence and mortality have been changing for many reasons. We performed a thorough investigation of incidence and mortality trends of RCC in the United States using the cell Surveillance, Epidemiology, and End Results (SEER) database. PATIENTS AND METHODS: The 13 SEER registries were accessed for RCC cases diagnosed between 1992 and 2015. Incidence and mortality were calculated by demographic and tumor characteristics. We calculated annual percentage changes of these rates. Rates were expressed as 100,000 person-years.
RESULTS: A total of 104,584 RCC cases were reviewed, with 47,561 deaths. The overall incidence was 11.281 per 100,000 person-years. Incidence increased by 2.421% per year (95% confidence interval, 2.096, 2.747; P < .001) but later became stable since 2008. However, the incidence of clear-cell subtype continued to increase (1.449%; 95% confidence interval, 0.216, 2.697; P = .024). RCC overall mortality rates have been declining since 2001. However, mortality associated with distant RCC only started to decrease in 2012, with an annual percentage change of 18.270% (95% confidence interval, -28.775, -6.215; P = .006).
CONCLUSION: Despite an overall increase in the incidence of RCC, there has been a recent plateau in RCC incidence rates with a significant decrease in mortality.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Kidney cancer; Mortality; Renal cell carcinoma; SEER

Mesh:

Year:  2018        PMID: 30391138      PMCID: PMC6348014          DOI: 10.1016/j.clgc.2018.10.002

Source DB:  PubMed          Journal:  Clin Genitourin Cancer        ISSN: 1558-7673            Impact factor:   2.872


  41 in total

1.  Permutation tests for joinpoint regression with applications to cancer rates.

Authors:  H J Kim; M P Fay; E J Feuer; D N Midthune
Journal:  Stat Med       Date:  2000-02-15       Impact factor: 2.373

2.  Cancer statistics, 2018.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-01-04       Impact factor: 508.702

3.  Translocation carcinomas of the kidney after chemotherapy in childhood.

Authors:  Pedram Argani; Marick Laé; Edgar T Ballard; Mahul Amin; Carlos Manivel; Brian Hutchinson; Victor E Reuter; Marc Ladanyi
Journal:  J Clin Oncol       Date:  2006-04-01       Impact factor: 44.544

4.  Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial.

Authors:  Toni K Choueiri; Susan Halabi; Ben L Sanford; Olwen Hahn; M Dror Michaelson; Meghara K Walsh; Darren R Feldman; Thomas Olencki; Joel Picus; Eric J Small; Shaker Dakhil; Daniel J George; Michael J Morris
Journal:  J Clin Oncol       Date:  2016-11-14       Impact factor: 44.544

Review 5.  Epidemiology and risk factors for kidney cancer.

Authors:  Wong-Ho Chow; Linda M Dong; Susan S Devesa
Journal:  Nat Rev Urol       Date:  2010-05       Impact factor: 14.432

Review 6.  The Role of Tobacco Smoke in Bladder and Kidney Carcinogenesis: A Comparison of Exposures and Meta-analysis of Incidence and Mortality Risks.

Authors:  Marcus G Cumberbatch; Matteo Rota; James W F Catto; Carlo La Vecchia
Journal:  Eur Urol       Date:  2015-07-03       Impact factor: 20.096

7.  Body mass index and survival in patients with renal cell carcinoma: a clinical-based cohort and meta-analysis.

Authors:  Yuni Choi; Bumsoo Park; Byong Chang Jeong; Seong Il Seo; Seong Soo Jeon; Han Yong Choi; Hans-Olov Adami; Jung Eun Lee; Hyun Moo Lee
Journal:  Int J Cancer       Date:  2012-06-20       Impact factor: 7.396

8.  Contrast-enhanced ultrasound of the kidney: a single-institution experience.

Authors:  Sheng F Oon; Robert W Foley; Deirdre Quinn; David M Quinlan; Robert G Gibney
Journal:  Ir J Med Sci       Date:  2017-12-07       Impact factor: 1.568

Review 9.  Recent advances in localized RCC: A focus on VEGF and immuno-oncology therapies.

Authors:  Pearl Subramanian; Naomi B Haas
Journal:  Urol Oncol       Date:  2017-10-16       Impact factor: 3.498

10.  Is Ultrasound Useful for Further Evaluation of Homogeneously Hyperattenuating Renal Lesions Detected on CT?

Authors:  Mahadevaswamy Siddaiah; Satheesh Krishna; Matthew D F McInnes; Jeffrey S Quon; Wael M Shabana; Demetri Papadatos; Nicola Schieda
Journal:  AJR Am J Roentgenol       Date:  2017-07-05       Impact factor: 3.959

View more
  44 in total

1.  Comparative Survival Associated With Use of Targeted vs Nontargeted Therapy in Medicare Patients With Metastatic Renal Cell Carcinoma.

Authors:  Pengxiang Li; Jordan Jahnke; Amy R Pettit; Yu-Ning Wong; Jalpa A Doshi
Journal:  JAMA Netw Open       Date:  2019-06-05

2.  Factors Associated With Receipt of Partial Nephrectomy or Minimally Invasive Surgery for Patients With Clinical T1a and T1b Renal Masses: Implications for Regionalization of Care.

Authors:  Joshua Sterling; Zorimar Rivera-Núñez; Hiren V Patel; Nicholas J Farber; Sinae Kim; Kushan D Radadia; Parth K Modi; Sharad Goyal; Rahul Parikh; Robert E Weiss; Isaac Y Kim; Sammy E Elsamra; Thomas L Jang; Eric A Singer
Journal:  Clin Genitourin Cancer       Date:  2020-03-20       Impact factor: 2.872

Review 3.  Systematic Review of Contemporary Evidence for the Management of T1 Renal Cell Carcinoma: What IRs Need to Know for Kidney Cancer Tumor Boards.

Authors:  Julie Cronan; Sean Dariushnia; Zachary Bercu; Robert Mitchell Ermentrout; Bill Majdalany; Laura Findeiss; Janice Newsome; Nima Kokabi
Journal:  Semin Intervent Radiol       Date:  2019-08-19       Impact factor: 1.513

Review 4.  Bosniak Classification of Cystic Renal Masses, Version 2019: An Update Proposal and Needs Assessment.

Authors:  Stuart G Silverman; Ivan Pedrosa; James H Ellis; Nicole M Hindman; Nicola Schieda; Andrew D Smith; Erick M Remer; Atul B Shinagare; Nicole E Curci; Steven S Raman; Shane A Wells; Samuel D Kaffenberger; Zhen J Wang; Hersh Chandarana; Matthew S Davenport
Journal:  Radiology       Date:  2019-06-18       Impact factor: 11.105

5.  Molecular Characterization of m6A Modifications in Non-Clear Cell Renal Cell Carcinoma and Potential Relationship with Pathological Types.

Authors:  Xuebao Xiang; Yi Guo; Zhongyuan Chen; Zengnan Mo
Journal:  Int J Gen Med       Date:  2022-02-15

Review 6.  The Role of Lymph Node Dissection for Non-Metastatic Renal Cell Carcinoma: An Updated Systematic Review and Meta-Analysis.

Authors:  Xu Shi; Dechao Feng; Dengxiong Li; Facai Zhang; Wuran Wei
Journal:  Front Oncol       Date:  2022-01-12       Impact factor: 6.244

7.  Kidney cancer trends and risk factors in Lebanon: a 12-year epidemiological study.

Authors:  Elise Assouad; Said El Hage; Steven Safi; Antonio El Kareh; Elie Mokled; Pascale Salameh
Journal:  Cancer Causes Control       Date:  2021-11-28       Impact factor: 2.506

8.  Elective Cytoreductive Nephrectomy After Checkpoint Inhibitor Immunotherapy in Patients With Initially Unresectable Metastatic Clear Cell Renal Cell Carcinoma.

Authors:  Melissa A Reimers; Robert S Figenshau; Eric H Kim; Julie Tucker; Nicole Kasten; Adeel S Khan; Jan M Hanneken; Zachary L Smith; James J Hsieh
Journal:  Clin Genitourin Cancer       Date:  2020-04-20       Impact factor: 2.872

9.  Real-World Outcomes Among US Veterans Health Administration Patients Newly Diagnosed with Metastatic Renal Cell Carcinoma and Treated with First-Line Monotherapy.

Authors:  Abhijeet Bhanegaonkar; Shivani Pandya; Ying Zheng; Ruth Kim; Stan Krulewicz; Vijay Kasturi; Hemant Phatak
Journal:  Adv Ther       Date:  2021-04-17       Impact factor: 3.845

10.  Cabozantinib and dasatinib synergize to induce tumor regression in non-clear cell renal cell carcinoma.

Authors:  Hui-Wen Lue; Daniel S Derrick; Soumya Rao; Ahna Van Gaest; Larry Cheng; Jennifer Podolak; Samantha Lawson; Changhui Xue; Devin Garg; Ralph White; Christopher W Ryan; Justin M Drake; Anna Ritz; Laura M Heiser; George V Thomas
Journal:  Cell Rep Med       Date:  2021-05-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.